MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed ...

This 68-year-old white male diagnosed with acute myelogenous leukemia presented with an ankle lesion (see Figure 1). The lesion was biopsied, which revealed Fusarium with dermal hemorrhage.

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...